FDA Approves Actemra for the Treatment of Moderately to Severely Active Rheumatoid Arthritis

Links shared publicly online about this topic.

  • 1,463
    total visits

FDA Approves Actemra for the Treatment of Moderately to Severely Active Rheumatoid Arthritis

drugs.com

Actemra (tocilizumab) is used to treat rheumatoid arthritis. Includes Actemra side effects, interactions and indications.

View full resource at drugs.com

Tags: Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis Medication, FDA, Actemra

  • Share

Most Recently Shared on January 21, 2010 at 3:07 pm By:

LegalMeds LegalMedsDirect

FDA Approves New Medicaton for the Treatment of Moderately to Severely Active Rheumatoid Arthritis....http://bit.ly/6zMqvp

2 years ago...

Also Shared By:

Drugs.com Drugs.com

ACTEMRA (tocilizumab) | Rheumatoid Arthritis Treatment

actemra.com — “Find information about ACTEMRA, an FDA-approved treatment for rheumatoid arthritis. ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well. ACTEMRA is used to treat people with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older. SoView full resource at actemra.com

  • View Related
  • Share

Most Recently Shared on January 20, 2012 at 3:35 pm By:

Actemra gains indication for inhibition and improvement of RA - MPR

empr.com — “Genentech announced that the FDA has approved Actemra (tocilizumab injection) for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis (RA), when given in combination with methotrexate (MTX).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on January 5, 2011 at 6:12 pm By:

eMPR MPR Medical Publisher

MPR News: Actemra gains indication for inhibition and improvement of RA: Genentech announced that the FDA has ap... http://bit.ly/ebgisU

1 year ago...

Actemra gains indication for inhibition and improvement of RA - ONA

oncologynurseadvisor.com — “Genentech announced that the FDA has approved Actemra (tocilizumab injection) for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis (RA), when given in combination with methotrexate (MTX).View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on January 5, 2011 at 6:06 pm By:

American Autoimmune Related Diseases Association (AARDA) Statement On The FDA Approval Of A New Treatment For Rheumatoid Arthritis

medicalnewstoday.com — “Friday, january 8, 2010, the food and drug administration (fda) approved actemra® (tocilizumab), a new biologic response modifier for adult patients with moderately to severely active rheumatView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on January 13, 2010 at 3:11 pm By:

mnt_arthritis MNT Arthritis News Health News

American Autoimmune Related Diseases Association (AARDA) Statement On The FDA Approval Of A New Treatment For Rheumato... http://mnt.to/3wdR

2 years ago...

American Autoimmune Related Diseases Association (AARDA) Statement on the FDA Approval of a New Treatment for Rheumatoid Arthritis

newswise.com — “Friday, January 8, 2010, the Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab), a new biologic response modifier for adult patients with moderately to severely active rheumatoid arthritis (RA).View full resource at newswise.com

  • View Related
  • Share

Most Recently Shared on January 12, 2010 at 9:26 pm By:

mednewswise Thom Canalichio Health News

American Autoimmune Related Diseases Association (AARDA) Statement on the FDA Approval of a New Treatment for Rheu... http://bit.ly/5nFgFQ

2 years ago...

FDA Approves ACTEMRA(R) (tocilizumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

medicalnewstoday.com — “Genentech, inc., a wholly owned member of the roche group (six: ro, rog; otcqx: rhhby), today announced that the u.s. food and drug administration (fda) approved actemra® (tocilizumab) for theView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on January 11, 2010 at 5:07 pm By:

mnt_arthritis MNT Arthritis News Health News

FDA Approves ACTEMRA(R) (tocilizumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis http://mnt.to/3w8r

2 years ago...

Actemra approved for moderately to severely active rheumatoid arthritis - MPR

empr.com — “The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on January 11, 2010 at 3:00 pm By:

eMPR MPR Medical Publisher

MPR News: Actemra approved for moderately to severely active rheumatoid arthritis: The FDA has approved Actemra (t... http://bit.ly/8WioYm

2 years ago...

FDA Approves ACTEMRA for the Treatment of Moderately to Severely Active Rheumatoid Arthritis | Pharmaceutical Processing

pharmpro.com — “Roche today announced that the FDA approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.View full resource at pharmpro.com

  • View Related
  • Share

Most Recently Shared on January 11, 2010 at 1:27 pm By:

FierceBiotech FierceBiotech Health News

RT @PharmProEditor: #FDA Approves ACTEMRA for the Treatment of Moderately to Severely Active Rheumatoid Arthritis http://bit.ly/5AiTH4

2 years ago...

Advertisement